Breast Cancer Management in the TAILORx Era: Less is More
Introduction Breast cancer is the most common malignancy among women in the United States, with over 260,000 new cases and over 40,000 de
Read MoreDecember 17, 2018
Comments are off
Expanding the Role of N-of-1 Trials in the Precision Medicine Era: Action Priorities and Practical Considerations
Heterogeneous responses to the same therapy among individual patients are commonp
Read MoreDecember 10, 2018
Comments are off
A Proposed Approach for Implementing Genomics-Based Screening Programs for Healthy Adults
The central idea of early disease detection and treatment is essentially simple. However, the path to its succe
Read MoreDecember 03, 2018
Comments are off
Moving Data Sharing Forward: The Launch of the Vivli Platform
Introduction On January 14, 2015, the Institute of Medicine (IOM) released a consensus study report titled Sharing Clinical Trial Data: Maxi
Read MoreNovember 19, 2018
Comments are off
Cancer Prevention and Control: Then and Now
Controlling or reducing the risk for cancer was a principal goal of the National Cancer Act, signed by President Nixon in 1971. Long before the human genome w
Read More
A Vision for a Person-Centered Health Information System
Introduction The person-centered health information system (PCHIS) of the future leverages information technology enhanced by artificial
Read More
The Evolving Case for Public-Private Partnerships to Achieve the Global Goals
Upon arriving in Kenya in 1987, I was a well-trained parasitologist who knew nothing about development, economics, p
Read More
Clinical Perspectives on Obesity Treatment: Challenges, Gaps, and Promising Opportunities
Introduction In April 2017, the Roundtable on Obesity Solutions of the National Academies of Sciences, Engineering
Read MoreSeptember 10, 2018
Accelerating Precision Health by Applying the Lessons Learned from Direct-to-Consumer Genomics to Digital Health Technologies
Emerging Opportunities for Digital Health Digital health technologies have
Read More
It’s Time to Harmonize Clinical Trial Site Standards
Climbing costs and lengthy time frames of clinical trials are significant bottlenecks in medical product development. Despite the fact that scientifi
Read More
